| Similar Articles |
|---|
 |
Bio-IT World
June 12, 2002
Kevin Davies |
Variations on a Theme Researchers at Genaissance Pharmaceuticals have outlined the path to creating a comprehensive map of human genomic variation that should ultimately reveal the genetic underpinnings of common diseases.   |
BusinessWeek
November 7, 2005
Catherine Arnst |
How Likely Are You To Get Sick? A new DNA database could gauge your risk for disease. |
BusinessWeek
October 23, 2008 |
The Story in Your Genes There's tremendous value in genetic data, but it depends on how deeply you look. |
Bio-IT World
Dec 2006/Jan 2007
Kevin Davies |
The One Percent Difference New research reveals a shocking new layer of human genome variation with profound implications for the future of genomic analysis and personalized medicine. |
Bio-IT World
March 2006
Kevin Davies |
Clinical Data Launches Landmark Trial Clinical Data has launched a Phase III clinical trial for the depression drug vilazodone and will concurrently develop a diagnostic test. The study could prove to be a landmark event in pharmacogenomic medicine. |
Bio-IT World
January 13, 2003
Jennifer Lorenzetti |
Taking Data Storage to Infinity -- and Beyond Perlegen Sciences has made important advances in resequencing DNA and identifying SNPs (single nucleotide polymorphisms), to the point that an entire human genome can be deduced in about 10 days. But it requires storing an extraordinary amount of data -- here's how it's done. |
Chemistry World
January 20, 2011
James Urquhart |
SNPs on display DNA origami and atomic force microscopy have been combined to reliably detect and image single nucleotide polymorphisms, the most common form of genetic variation in the human genome. |
Bio-IT World
July 2005 |
News Blast Applied Allied... Third Phase... Broad Broadens... In the Pipeline... |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
Bio-IT World
May 2006
Kevin Davies |
Personalized Medicine's Rosy Picture GlaxoSmithKline's head of genetics research, Allen Roses, says that pharmacogenetics is having a profound impact on the stratifying of patients, the minimization of adverse events, and the expedited passage of drug candidates through clinical trials. |
The Motley Fool
June 12, 2009
Brian Orelli |
Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side. |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
Bio-IT World
February 18, 2004 |
The Quest for Complex Genes Genetic sleuths are homing in on genes for complex diseases with the help of new, and some not so new, tools and strategies. |
The Motley Fool
September 28, 2006
Brian Lawler |
Myriad Moves Forward The biotech's new cancer candidate passes phase 1 trials. Investors should take note, and make room for Myriad on their radar screens. |
The Motley Fool
September 20, 2007
Brian Orelli |
Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note. |
Fast Company
December 2009
Erica Westly |
The Price of Winning FDA Approval Approval for a new drug or medical treatment requires extensive -- and expensive -- human trials for safety and effectiveness. |
InternetNews
April 19, 2010 |
Oracle Grabs Health Software Firm Phase Forward In an all-cash deal, Oracle is shelling out $685 million to purchase Phase Forward, a Massachusetts-based firm specializing in software to manage drug data and health science. |
Popular Mechanics
November 19, 2009
Joe P. Hasler |
Top 6 North American Meteor Showers You Don't Want to Miss A list of upcoming meteor spectacles in the sky. |
The Motley Fool
September 11, 2007
Brian Orelli |
A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note. |
Bio-IT World
May 2006
Kevin Davies |
Trailblazers Test Public Markets Three companies in postgenomic fields are going public. Infinity Pharmaceuticals, Perlegen Sciences, and Entelos announced they would be entering the public markets by means of merger, IPO, and institutional offering. |
BusinessWeek
June 13, 2005
John Carey |
The NIH's Roadmap for Research Charting the human genome was just the beginning. Now the focus is creating pathways that will lead to practical applications. |
Wired
November 17, 2007
Thomas Goetz |
23AndMe Will Decode Your DNA for $1,000. Welcome to the Age of Genomics A much-anticipated Silicon Valley startup called 23andMe offers a thorough tour of your genealogy, tracing your DNA back through the eons. |
Bio-IT World
April 15, 2003
Malorye Branca |
Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease? |
The Motley Fool
May 29, 2008
Brian Lawler |
Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing. |
American Journal of Nursing
October 2009 |
Pharmacogenomics: Personalizing Drug Therapy Pharmacogenomics is a rapidly growing field of research into the ways in which genetic variation affects drug response. |
Bio-IT World
June 2005
Kevin Davies |
First Base: Genes, Geography, and History The National Genographic Project will collect blood samples from populations around the globe, then use genetic data to trace population origins and migration routes. Some groups are critical. |
Bio-IT World
June 2006
Graeme O'Neill |
Why Variety Is the Spice of Life In an effort to bring order to the field of single nucleotide polymorphism research data collection and management, pioneering mutation hunter Richard Cotton has organized The Human Variome Project Meeting in Melbourne, Australia. |
Bio-IT World
September 9, 2002
Kevin Davies |
The Debate Over Race Relations Are self-identified labels of race useful in large-scale population genetic studies? A provocative commentary from a leading Stanford University geneticist has fuelled controversy. |
Pharmaceutical Executive
May 1, 2009 |
The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
Bio-IT World
September 9, 2002
Malorye Branca |
The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems. |
Bio-IT World
Jul/Aug 2006
Kevin Davies |
Beyond the Last Chromosome About 700 attendees gathered Beyond Genome 2006, one of Cambridge Healthtech Institute's flagship conferences, to discuss the major technology trends in postgenomic biology, including systems biology, RNAi, proteomics, and personalized medicine. |
The Motley Fool
March 8, 2007
Selena Maranjian |
Collect Underwear and Retire Rich If Phase 1 is save money for retirement, and phase 3 is retire, then there's a very important Phase 2: Invest intelligently. One shortcut is to simply invest in a broad-market index fund that also charges a bargain-basement expense ratio. |
The Motley Fool
July 25, 2007
Brian Orelli |
Shiny Happy Illumina Illumina, which makes chips that can distinguish one million different genes, announced another stellar quarter. That makes eight in a row. |
The Motley Fool
April 26, 2007
Tom Taulli |
Phase Forward's False Funk Ignore its stagnant shares -- new deals should continue this company's growth. |
Bio-IT World
October 14, 2004
Kevin Davies |
Galileo Opts for Illumina Beads Following a successful gene-mapping partnership with one California high-tech company, Montreal-based Galileo Genomics is turning to another to finish the job. |
The Motley Fool
December 29, 2006
Brian Lawler |
Is Threshold on the Verge of Success? Shares of Threshold Pharmaceuticals were the second-best performer on the market yesterday, up 28% as a result of positive phase 2 clinical trial results for its lead drug, glufosfamide. |
BusinessWeek
May 9, 2005 |
A Genome Pioneer Looks Forward Dr. Francis Collins discusses the end of the Human Genome Project and says an "outpouring of discoveries" is coming soon. |
Bio-IT World
June 2005
Robert M. Frederickson |
Crime Pays for DNAPrint Genomics DNAWITNESS 2.0 is used by law enforcement agencies to determine the likely genetic heritage of DNA samples obtained from crime scenes -- thereby narrowing the potential pool of suspects or victims. |
Pharmaceutical Executive
October 1, 2006
Clinton & Koroneos |
Learn & Confirm At Wyeth, a sweeping set of initiatives is transforming the R&D operation - and spotlighting a possible future for drug development. |
Managed Care
August 2004
Thomas Morrow |
10,000 Cells on a Chip Signal Start of New Era of Diagnosis Diseases will soon be defined by biochemical pathways and genetic interactions. Biochips may identify patients likely to respond to therapeutic agents. All of this is a big deal for health plans. |
Bio-IT World
February 11, 2005
Kevin Davies |
The Galileo Code In searching 400 years of French-Canadian history for genetic clues to diseases among Quebec's founding population, Genizon BioSciences -- formerly Galileo Genomics -- is rapidly becoming the bio-IT company du jour. |
The Motley Fool
November 14, 2011
Brian Orelli |
Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up. |
